Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents
Open Access
- 1 March 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Targeted Oncology
- Vol. 5 (1), 65-72
- https://doi.org/10.1007/s11523-010-0137-6
Abstract
The emergence of molecularly targeted agents in oncology has not only revolutionized the care of cancer patients, but also changed the daily practice of medical oncologists. Molecularly targeted agents indeed often differ from traditional cytotoxic agents by their administration schedules and routes, their toxicity profiles, and/or the assessment of their antitumor activity. In addition, the observation that molecularly targeted agents sometimes have limited antitumor activity as single agents has led clinical investigators to combine molecularly targeted agents together or with cytotoxic agents. We review here the current challenges for the early clinical development of anticancer agents in the era of molecularly targeted agents. We focus on the choice of end points in phase I oncology clinical trials, as well as on the choice of dose escalation methods with an emphasis on available dose escalation methods for molecularly targeted agents and for combination trials.This publication has 67 references indexed in Scilit:
- Management and interpretation of novel toxicities of molecular targeted therapies: Renal toxicitiesEuropean Journal of Cancer, 2009
- Inhibition of the Hedgehog Pathway in Advanced Basal-Cell CarcinomaNew England Journal of Medicine, 2009
- Skin toxicities of targeted therapiesEuropean Journal Of Cancer, 2009
- Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?British Journal of Cancer, 2009
- Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experienceBritish Journal of Cancer, 2008
- Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave RoussyAnnals Of Oncology, 2007
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004